ADPT vs NEO
ADPT: Adaptive Biotechnologies uses its proprietary immune medicine platform to decode the adaptive immune system for precision diagnostics in cancer and targeted therapeutic discovery. NEO: NeoGenomics is a clinical laboratory leader providing specialized cancer-focused genetic and molecular testing services for diagnostics and pharmaceutical research.
Side-by-side fundamentals
| Metric | ADPT | NEO | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $22.57 | $13.14 | |
| Market cap as of 2026-08-03 | $3.6B | $1.7B | |
| PEG as of 2026-08-03 | n/a | 1.27 | |
| Net margin as of 2026-08-03 | -16.8% | -13.3% | NEO higher |
| Gross margin as of 2026-08-03 | +75.3% | +43.1% | ADPT higher |
| Operating margin as of 2026-08-03 | -15.8% | -14.3% | NEO higher |
| ROE as of 2026-08-03 | -24.3% | -11.8% | NEO higher |
| ROA as of 2026-08-03 | -9.9% | -7.2% | NEO higher |
| Debt / equity as of 2026-08-03 | 0.60 | 0.41 | NEO lower |
| Revenue growth (YoY) as of 2026-08-03 | +55.9% | +10.9% | ADPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.3% | n/a | |
| Beta as of 2026-08-03 | 1.69 | 1.78 | |
| 1-year return as of 2026-07-31 close | +120.4% | +108.9% | ADPT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.